Welcome to our dedicated page for Zai Lab SEC filings (Ticker: ZLAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Zai Lab Limited filings document the SEC reporting record for its American depositary shares and the governance and financing disclosures of a Cayman Islands biopharmaceutical issuer. Form 8-K reports furnish quarterly and annual operating results, financial-condition updates and clinical or regulatory corporate updates tied to its oncology, immunology, neuroscience and infectious disease programs.
The filing record also includes proxy materials covering annual meeting matters, board governance, executive compensation and equity awards. Material-event reports describe capital-structure and liquidity matters, including working-capital credit arrangements, guarantees for Zai Lab Shanghai and related covenant disclosures, while ADR disclosures distinguish the SEC-registered depositary shares from ordinary shares listed in Hong Kong.
Zai Lab Ltd director William Lis sold 7,040 American Depositary Shares in an open-market transaction. The sale occurred at a price of $18.09 per ADS. After this transaction, he directly holds 50,437 ADS.
Each ADS represents ten Ordinary Shares, and the company states that ADSs and Ordinary Shares are fully fungible. The sale was carried out under a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2025, indicating the trades were pre-arranged rather than opportunistic.
GAYNOR RICHARD reported acquisition or exercise transactions in this Form 4 filing.
Zai Lab Ltd director Richard Gaynor received a stock grant in the form of American Depositary Shares (ADSs). On June 17, 2026, he was awarded 22,371 ADSs at no cash cost as a compensation-related grant. Following this award, he directly holds 79,001 ADSs. Each ADS represents ten ordinary shares of Zai Lab, and the ADSs and ordinary shares are fully fungible. The granted shares are restricted and will vest in full on June 17, 2027, provided he continues to serve on the company’s board of directors through that date.
Morrison Scott W reported acquisition or exercise transactions in this Form 4 filing.
Zai Lab Ltd director Morrison Scott W received a grant of 22,371 American Depositary Shares as equity compensation. The award was made at a price of $0.00 per ADS and consists of restricted shares that vest in full on June 17, 2027, contingent on his continued board service. Following this grant, he directly holds a total of 56,904 ADS. Each ADS represents ten ordinary shares of Zai Lab, and the filing reports all amounts in ADS terms.
Lis William reported acquisition or exercise transactions in this Form 4 filing.
Zai Lab Ltd director William Lis received a grant of 22,371 American Depositary Shares as equity compensation. The award was made at no cash cost per ADS and increases his direct holdings to 57,477 ADS.
The granted ADS are restricted shares that vest in full on June 17, 2027, if he continues serving on the board. Each ADS represents ten ordinary shares, and the company notes that ADSs and ordinary shares are fully fungible.
Vounatsos Michel reported acquisition or exercise transactions in this Form 4 filing.
Zai Lab Ltd director Michel Vounatsos received an equity award of 22,371 American Depositary Shares (ADS), reported at a price of $0.00 per ADS, as a grant or award. These are restricted shares that vest in full on June 17, 2027, if he continues serving on the board through that date.
Following this grant, Vounatsos directly holds 72,787 ADS. Each ADS represents ten ordinary shares of Zai Lab, and the company states that its ADSs and ordinary shares are fully fungible.
DIEKMAN JOHN D reported acquisition or exercise transactions in this Form 4 filing.
Zai Lab Ltd director John D. Diekman received an equity award of 22,371 American Depositary Shares as a grant, with no cash paid per share. These are restricted shares that will vest in full on June 17, 2027, as long as he continues serving on the board through that date. Following this award, he directly holds a total of 122,140 American Depositary Shares in the company.
WIRTH PETER reported acquisition or exercise transactions in this Form 4 filing.
Zai Lab Ltd director Peter Wirth received a grant of 22,371 American Depositary Shares (ADSs) as a stock award. The filing notes these are restricted shares that vest in full on June 17, 2027, if he continues serving on the board. After this grant, he directly holds 416,121 ADSs. Each ADS represents ten ordinary shares, and the award was made at no cash purchase price, reflecting equity-based director compensation rather than an open-market share purchase.
Leung Nisa reported acquisition or exercise transactions in this Form 4 filing.
Zai Lab Ltd director Nisa Leung received a stock grant of 22,371 American Depositary Shares (ADS) as compensation. These are restricted shares that vest in full on June 17, 2027, contingent on her continued service on the board. Following this award, she directly holds 96,297 ADS in total.
MOULDER LEON O JR reported acquisition or exercise transactions in this Form 4 filing.
Zai Lab Ltd director Leon O. Moulder Jr received a grant of 22,371 American Depositary Shares (ADS) as a compensation award. The shares were granted at $0.00 per ADS and are described as restricted shares that vest in full on June 17, 2027, if he continues serving on the board. Each ADS represents ten ordinary shares of Zai Lab, and following this grant he directly holds 94,973 ADS in total. This is a stock-based award rather than an open-market purchase or sale.